Episealer® Knee System IDE Clinical Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT04000659

Recruitment Status : Recruiting

First Posted : June 27, 2019

Last Update Posted : March 7, 2024

See Contacts and Locations

View this study on the modernized ClinicalTrials.gov

Sponsor:

Collaborator:

MCRA

Information provided by (Responsible Party):

Episurf Medical Inc.

Study Description

Brief Summary:

The study is a randomized, prospective, multicenter, controlled clinical trial of the Episealer Knee System. The Episealer Knee System is intended for subjects with up to two focal femoral knee chondral or osteochondral lesion that is causing pain and/or disability and requires surgical treatment.

Condition or disease	Intervention/treatment	Phase
Degenerative Lesion of Articular Cartilage of Knee	Device: Episealer Knee System Procedure: Microfracture	Not Applicable

Detailed Description:

The primary objective of this study is to evaluate the safety and clinical effectiveness of the Episealer Knee System (Episealer Trochlea Solo, Episealer Femoral Twin, and Episealer Condyle Solo) compared to microfracture (with or without debridement) in a group of subjects that require repair of up to 2 focal femoral chondral or osteochondral lesions in the knee.

Clinical success will be analyzed via subject reported outcomes to measure function and pain improvements as compared to baseline, incidence of secondary surgical interventions for the treated knee, absence of subsidence or migration through radiographic assessment, and assessment of weight-bearing status.

Study Design

Layout table for study information

Study Type :	Interventional (Clinical Trial)
Estimated Enrollment :	180 participants
Allocation:	Randomized
Intervention Model:	Parallel Assignment
Intervention Model Description:	A total of 180 subjects will be enrolled and randomized using a 2:1 ratio (Episealer: Microfracture). Within each site, subjects will be randomized into one of the two study arms using a blocked randomization scheme with varying block sizes.
Masking:	Single (Participant)
Masking Description:	In this investigation, neither the investigator nor the subject can be blinded to the treatment group assignment due to the implant's distinctive form that can be detected on radiographs; however, the randomization assignment will not be disclosed to the subject until after surgery is performed.
Primary Purpose:	Treatment
Official Title:	A Prospective, Randomized, Controlled, Multi-Center Study to Evaluate the Safety and Effectiveness of the Episealer® Knee System Compared to Microfracture for the Treatment of Focal Femoral Knee Chondral or Osteochondral Lesions
Actual Study Start Date :	June 18, 2020
Estimated Primary Completion Date :	June 2026
Estimated Study Completion Date :	June 2028

Arms and Interventions

Arm	Intervention/treatment
Experimental: Episealer Knee System The experimental arm will comprise of subjects that will be treated with the Episealer Knee System.	Device: Episealer Knee System The Episealer Knee System is comprised of individualized endoprosthetic resurfacing implants and implantation tools (Episealer Toolkit). The implants are designed to replace the articulating surface which has been damaged due to femoral knee chondral and osteochondral defects.
Placebo Comparator: Microfracture The control arm will comprise of subjects that will receive a Microfracture surgery.	Procedure: Microfracture Microfracture is a minimally invasive surgical technique developed to repair defects in articular cartilage and reduce pain in the knee joint. Microfracture techniques are described in the orthopedic literature and are performed arthroscopically.

Outcome Measures

Primary Outcome Measures :

Change in the Knee Injury & Osteoarthritis Outcome Score (KOOS) Subscores [ Time Frame: 24 Months ]
This endpoint will examine the change in KOOS subscores at 24 months
Change in Visual Analog Scale (VAS) Pain Scores [ Time Frame: 24 Months ]
This endpoint will examine the change in VAS Pain scores at 24 months
Incidence of Secondary Surgical Intervention [ Time Frame: 24 Months ]
This endpoint will examine the incidence of Secondary Surgical Interventions (SSIs) at 24 months
Incidence of subsidence or migration at 24 months [ Time Frame: 24 Months ]
This endpoint will examine the incidence of subsidence/migration at 24 months
Weight bearing status [ Time Frame: 8 weeks ]
This endpoint will examine the weight bearing status at 8 weeks

Secondary Outcome Measures :

Change in the KOOS Subscores at all follow-up time points [ Time Frame: 3-weeks, 8-weeks, 6-months, 12-months, and 24-months ]
This endpoint will examine the change in KOOS subscores at all follow-up time points
Change in VAS Pain score at all follow-up time points [ Time Frame: 3-weeks, 8-weeks, 6-months, 12-months, and 24-months ]
This endpoint will examine the change in VAS Pain scores at all follow-up time points
Change in 12-Item Short Form Survey (SF-12) score at all follow-up time points [ Time Frame: 3-weeks, 8-weeks, 6-months, 12-months, and 24-months ]
This endpoint will examine the change in SF-12 scores at all follow-up time points
Incidence of radiographic findings at all follow-up time points [ Time Frame: 8 weeks, 12-months, and 24-months ]
This endpoint will examine the incidence of radiographic findings at all follow-up time points
Incidence of adverse events and device deficiencies at all follow-up time points [ Time Frame: 3-weeks, 8-weeks, 6-months, 12-months and 24-months ]
This endpoint will examine the safety via the incidence of adverse events and device deficiencies at all follow-up time points

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information

Ages Eligible for Study:	30 Years to 70 Years (Adult, Older Adult)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

INCLUSION CRITERIA

Be ≥ 30 years and ≤ 70 years.
Have up to 2 symptomatic femoral chondral or osteochondral defects in the index knee on the medial or lateral femoral condyles or the knee trochlea area, which are:
1. ICRS Grade 2, 3 or Grade 4
2. Each suitable for treatment with 1 Episealer device NOTE: Additional femoral cartilage lesions which, in the opinion of the investigator, are asymptomatic and free from underlying bone lesions (e.g., bone edema) will not be treated.
Have focal articular defect(s) each with a cartilage lesion area ≥ 1.5 cm2 and ≤ 7.0 cm2.
1. Subjects with up to two defects ≥ 1.5 cm2 and ≤ 4.0 cm2, that are surrounded by adequate circumferential cartilage as determined by the investigator, will be randomized.
2. Subjects with at least one defect > 4.0 cm2 and ≤ 7.0 cm2, with adequate bony support as determined by the investigator, will not be randomized, and will receive the Episealer device.
Have screening scores that meet the following criteria:
1. Visual Analog Scale (VAS) pain score of the index knee of ≥ 40 mm
2. KOOS Overall Score of ≤ 60
Have experienced knee pain symptoms and undergone prior non-surgical management (e.g., physical therapy, bracing, HA injections) for at least 4 weeks prior to being considered for the study.
Be able to give voluntary, written informed consent to participate and have signed an Informed Consent Form specific to this study.
Be willing and able to comply with all study procedures including all pre-operative, post-operative, and rehabilitation requirements.

If female and of child-bearing potential, must have a negative pregnancy test prior to the surgical procedure and no intention of becoming pregnant in the next 24 months.

EXCLUSION CRITERIA

Pre-Operative Exclusion Criteria

Subjects who meet any of the following pre-operative screening criteria will be excluded from participation in this study:

Have a Body Mass Index (BMI) greater than 37 kg/m2.
Have an ICRS Grade 3 or 4 tibial lesion of any size, or an ICRS Grade 4 patella lesion/fissure ≥ 2.0 mm in width in the index knee.
Have malalignment of >8 degrees varus or valgus in the index knee based on standard AP x-rays.
Have deficits in flexion or extension of >10 degrees in the index knee as compared to the contralateral knee.
Have an existing prosthesis in the index knee compartment or opposing joint surface.
Have joint instability in the index knee due to soft tissue or muscular insufficiency.
Have a vascular insufficiency at the lesion site that will impair successful microfracture (e.g., avascular necrosis/osteonecrosis, osteochondritis dissecans). (NOTE: This exclusion will not apply to patients with lesions between 4.0-7.0 cm2 who will not undergo randomization and will be treated in the Episealer-only arm).
Have inadequate bone stock underlying the lesion site, in the opinion of the investigator.
Have any condition, therapy, or medication that may impair bone healing or prevent adequate implant fixation (e.g., osteoporosis).
Have a diagnosis of a concomitant knee injury, which in the opinion of the investigator, may confound assessment of the index knee.
Have any meniscus tears or defects that require resection of more than 1/3 of the meniscus in the compartment to be treated (i.e., medial meniscus when medial femoral compartment is being treated; lateral meniscus when lateral femoral compartment is being treated).
Have a contralateral knee with symptomatic cartilage, meniscal, or ligamentous lesions; generalized osteoarthritis, or any condition that requires surgery, which in the opinion of the investigator, may confound assessment of the index knee, or any condition that requires surgery.
Have any condition that is unrelated to the index knee and significantly impairs walking ability (e.g., spinal stenosis, sciatica).
Have undergone previous treatment with autograft or allograft transfer, synthetic plugs, or microfracture in the index knee within 6 months of screening. (NOTE: Subjects who have undergone debridement at any point in the past are not excluded).
Have a loss of joint space on standing radiographs (Kellgren-Lawrence Grade ≥3) in the index knee.
Have an active systemic infection, or an active local infection in or near the index knee, or a previous history of joint infection.
Have a history of rheumatoid arthritis.
Have known allergies to any of the materials used in the implant (i.e., Cobalt-Chrome alloy and Titanium).
Have a contraindication to MRI (e.g., implanted pacemaker, metallic cardiac valve(s), magnetic material such as surgical clips, stent, implanted electronic infusion pumps or any other condition that would prevent the subject from undergoing an MRI).
Have a known immunodeficiency including subjects who are receiving or have received corticosteroids, immunosuppressants, immunostimulating agents or radiation therapy within 6 months prior to surgery.
Are participating in another clinical investigation for which they received an investigational product (including, but not limited to, a drug or vaccine) within the last 60 days or report the intention to participate in another clinical investigation during the course of the study
Are currently abusing drugs or alcohol or have a history of the same within the last 6 months.
Have any mental or psychological disorder that would impair their ability to complete the study questionnaires.
Are currently breastfeeding or planning to breastfeed any time during the course of the study.
Are currently a prisoner.
Have significant comorbidities or conditions associated with high-risk for surgical or anesthetic survival (e.g., renal failure, peripheral vascular disease, unstable cardiac disease, poorly controlled diabetes, immunosuppression, etc.).
Have any medical condition or other circumstances, in the judgment of the investigator, that might interfere with the ability to return for follow-up visits, including any systemic illness, neuromuscular, neurosensory, or musculoskeletal deficiency that would render the subject unable to perform appropriate post-operative rehabilitation.
Have any condition which, in the judgment of the Investigator, would preclude adequate evaluation of the device's safety and performance.

Intra-operative Exclusion Criteria

Subjects who meet any of the following intra-operative screening criteria will be excluded from participation in this study:

Have any meniscus tears or defects that require resection of more than 1/3 of the meniscus in the compartment to be treated (i.e., medial meniscus when medial femoral compartment is being treated; lateral meniscus when lateral femoral compartment is being treated).
Have chondrosis of the non-operative patellofemoral compartment, contralateral compartment or medial or lateral proximal tibia greater than Outerbridge Grade 2.
Have an index lesion on the articular surface that lacks adequate circumferential cartilage as determined by the investigator (NOTE: This exclusion applies only to patients randomized to the microfracture arm.)

Applicable to Investigational Group Only
Have a defect undergoing treatment that cannot be adequately covered by the Episealer device based on intra-operative measurements.

Have bone quality which, in the judgment of the surgeon, would prevent satisfactory fixation of the investigational device.

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04000659

Contacts

Layout table for location contacts

Contact: Katarina Flodström	1 686 845 9447	Katarina.Flodstrom@episurf.com

Locations

Layout table for location information

United States, Arizona
Physicians Research Group	Recruiting
Tempe, Arizona, United States, 85284
Contact: Vianeth Santiago 480-868-7014 v.santiago@prgresearch.com
Contact: Tammy Fuentes 800-774-1534 t.fuentes@prgresearch.com
Principal Investigator: Eric Eifler, MD
United States, California
Horizon Clinical Research	Recruiting
La Mesa, California, United States, 91942
Contact: Dino Subasic, BS 619-456-6012 dino@horizontrials.com
Principal Investigator: Scott Hacker, MD
United States, Louisiana
Ochsner Sports Medicine Institute	Recruiting
New Orleans, Louisiana, United States, 70121
Contact: Faizan Chaudhry, MS 504-842-0263 faizan.chaudhry@ochsner.org
Contact: Susan Scariano (504)842-5291 susan.scariano@ochsner.org
Principal Investigator: Deryk Jones, MD
United States, New Jersey
Hackensack University Medical Center	Recruiting
Hackensack, New Jersey, United States, 07601
Contact: Rose Williams 551-996-4261 Rose.Williams@hackensackmeridian.org
Principal Investigator: Yair Kissin, MD
United States, New York
Plancher Orthopaedics & Sports Medicine	Recruiting
New York, New York, United States, 10128
Contact: Stephanie Petterson 203-869-2002 spetterson@ofals.org
Principal Investigator: Kevin Plancher, MD
United States, Ohio
Ohio State University	Recruiting
Columbus, Ohio, United States, 43202
Contact: Jenna DeFranco, BS 614-293-2761 Jenna.DeFranco@osumc.edu
Principal Investigator: David Flanigan, MD
United States, Tennessee
Helios Clinical Research	Recruiting
Jackson, Tennessee, United States, 38305
Contact: Brittany Reyes, BS 731-613-8248 breyes@crssites.com
Principal Investigator: Jason Hutchison, MD
United States, Texas
North Texas Medical Research Institute	Recruiting
Dallas, Texas, United States, 75254
Contact: Jeff Neumann, PA-C 817-903-0822 jneumann@dallasortho.net
Principal Investigator: Umar Burney, MD
Canada, Nova Scotia
QEII Health Sciences Center	Recruiting
Halifax, Nova Scotia, Canada, B3H 2E1
Contact: Liam Rappoldt 902-473-7626 liam@drivanwong.com
Contact: Morgan King morgan@drivanwong.com
Principal Investigator: Ivan Wong, MD
Germany
Universitatsmedizin Berlin Charite	Recruiting
Berlin, Germany, 10117
Contact: Derya Belkacem 030/450 615 196 derya.belkacem@charite.de
Contact: Anne Zergiebel 030/450 515 235 anne.zergiebel@charite.de
Principal Investigator: Tobias Jung, MD
Orthocentrum Hamburg	Recruiting
Hamburg, Germany, 20149
Contact: Rene Kaiser +4940443639 kaiser@oc-h.de
Principal Investigator: Johannes Holz, MD
United Kingdom
University Hospital Coventry and Warwickshire NHS Trust	Terminated
Coventry, England, United Kingdom, CV2 2DX
University Hospital Southampton NHS Foundation Trust	Terminated
Southampton, So16 6yd, United Kingdom
Robert Jones & Agnes Hunt Orthopaedic Hospital NHS Foundation Trust (RJAH)	Withdrawn
Oswestry, United Kingdom, Shropshire SY10 7AG

Sponsors and Collaborators

Episurf Medical Inc.

MCRA

Investigators

Layout table for investigator information

Study Director:	Katarina Flodström	Episurf Medical Inc.

More Information

Layout table for additonal information

Responsible Party:	Episurf Medical Inc.
ClinicalTrials.gov Identifier:	NCT04000659
Other Study ID Numbers:	IDE 1006
First Posted:	June 27, 2019 Key Record Dates
Last Update Posted:	March 7, 2024
Last Verified:	March 2024

Layout table for additional information

Studies a U.S. FDA-regulated Drug Product:	No
Studies a U.S. FDA-regulated Device Product:	Yes
Device Product Not Approved or Cleared by U.S. FDA:	Yes

Keywords provided by Episurf Medical Inc.:


Knee Cartilage

To Top